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Abstract

Objective: Pre-clinical evidence suggests delivery of nitric oxide (NO) through administration of inorganic nitrite suppresses arrhythmias resulting from acute ischaemia and reperfusion (I/R). To date no assessment of whether inorganic nitrite might limit reperfusion arrhythmia has occurred in man, therefore we explored the effects on I/R-induced ventricular arrhythmias in the NITRITE-AMI cohort.

Methods: In the NITRITE-AMI cohort, Holter analysis was performed prior to and for 24 hours after primary PCI in 80 patients who received either intra-coronary sodium nitrite (N=40) or placebo (N=40) during primary PCI for AMI. 

Results: Ventricular rhythm disturbance was experienced by 100% patients, however, there was no difference in the number between the groups, p=0.2196. Non-sustained ventricular tachycardia (NSVT) occurred in 67.5% (27/40) of nitrite-treated patients compared to 89% (35/39) of those treated with placebo (p=0.027). There was a significant reduction in both the number of runs (63%, p=<0.0001) and total beats of NSVT (64%, p=0.0019) in the nitrite-treated patients compared to placebo. Post-hoc analyses demonstrate a direct correlation of occurrence of NSVT with infarct size, with the correlation stronger in the placebo versus the nitrite group initimating an independent nitrite effect (Nitrite: r=0.110, p=0.499, placebo:  r=0.527, p=0.001, p for comparison: 0.004).  

Conclusion: Overall no difference in ventricular rhythm disturbance was seen with intra-coronary nitrite treatment during primary PCI in STEMI patients, however nitrite treatment was associated with an important reduction in the incidence and severity of NSVT. In view of the sustained reduction of MACE seen, this effect warrants further study in a large-scale trial.  


Introduction

Patients with acute myocardial infarction (AMI) are prone to developing potentially life-threatening ventricular arrhythmias such as ventricular tachycardia (VT) during the acute phase of the AMI. There is evidence that donors of nitric oxide (NO), for example by the administration of organic nitrites/nitrates (1), suppresses arrhythmia as a result of acute ischaemia and reperfusion in both animal models of an AMI (2, 3) but also in patients.  In particular, the administration of nitroglycerin in patients was associated with a reduced duration of ventricular ectopic beats over a 48 hour period following AMI (4, 5). Despite these observations this class of drug, the organic nitrate, is not routinely used to procure benefits in patients suffering AMI due to an overall absence of benefit in clinical trials in ST segment elevation myocardial infarction (STEMI) patients (6-8). However, there is growing evidence that alternative methods for NO delivery, due to differences in biochemistry, may be more efficacious in AMI, in particular delivery of NO from inorganic nitrate or nitrite (9-11)

Several reports indicate that inorganic nitrite is cardioprotective in pre-clinical models of AMI, reducing reperfusion injury (12, 13). Importantly, this research has been translated to the clinical setting with 2 separate studies assessing the effect of sodium nitrite on infarct size in patients presenting with ST elevation myocardial infarction (STEMI), namely NIAMI (14) and NITRITE-AMI (15). Whilst the administration of sodium nitrite intravenously prior to primary percutaneous coronary intervention (PCI) had no effect upon infarct size, when administered intra-coronary reductions in infarct size were apparent in patients with occluded arteries at the time of reperfusion (thrombolysis in myocardial infarction [TIMI] category 0-1)(). Whether these beneficial effects might also be accompanied by reductions in ventricular rhythm disturbance during primary PCI is yet to be determined.  However, support for this possibility comes from pre-clinical studies where intravenous infusion of sodium nitrite in a canine model of myocardial I/R injury resulted in a profound reduction in the severity and frequency of ventricular arrhythmias. This effect was attributed to delivery of NO specifically within the ischaemic environment possibly due to protein S-nitrosation of key components of mitochondrial respiratory chain and/or S-glutathionylation (16) and thus a localized reduction in oxidative stress. 

Thus, the aim of this sub-study was to assess the protective role of inorganic nitrite against acute ischaemia and reperfusion-induced ventricular arrhythmias in STEMI patients undergoing primary PCI in the NITRITE-AMI cohort. 


Methods

NITRITE-AMI Study design and participants 
NITRITE-AMI was a double-blind, randomised, single-centre, placebo-controlled trial to determine whether the intra-coronary injection of sodium nitrite reduces infarct size in patients with acute STEMI undergoing primary PCI. The trial was approved by an independent ethics committee, the Medicines and Healthcare Products Regulatory Agency, registered in approved registries (NCT01584453, EudraCT nr. 2011-000721-77) and performed in accordance with the Declaration of Helsinki (1996) and the principles of the International Conference on Harmonization–Good Clinical Practice (ICH-GCP) guidelines. Full details of the trial protocol have been published (17). All appropriate subjects gave written informed consent before being included in the study. After coronary angiography, patients were randomised (1:1) to a high-dose bolus injection of intra-coronary sodium nitrite (1.8 μmol in 10 mL of 0.9% NaCl) or placebo (10 mL of 0.9% NaCl) administered via an over the wire balloon positioned distal to the occlusion in the infarct related artery prior to balloon inflation. All study personnel were blind to treatment allocation until the study and all analyses had been completed. 

Ventricular Rhythm Monitoring
Each patient had a 24 hour Holter Monitor attached immediately after the primary PCI procedure in the cath lab prior to leaving for the coronary care unit (mean time from reperfusion to the placement of the Holter Monitor was 30.1 minutes). The Holter used was a Spacelabs cardiomemo attached with three leads and electrodes. Holter recordings underwent automated computer analysis by computer, with manual over-reading performed by The data was analysed by blinded trained cardiac physiologists with analysis focussed upon assessment of ventricular rhythm disturbance. Holter monitor recordings were specifically analysed for ventricular ectopy (isolated ventricular beats), the number of couplets, non-sustained ventricular tachycardia (NSVT) and accelerated idioventricular rhythm throughout the 24 hour period of monitoring. A couplet was defined as 2 consecutive ventricular ectopic beats. NSVT was defined as more than 3 ventricular ectopic beats at a rate of 120bpm or more that lasts for less than 30 seconds. Accelerated idioventricular rhythm was defined by more than 3 consecutive ventricular rhythm beats at a rate of less than 120bpm. Sustained VT was defined as a VT with a duration of more than 30 consecutive seconds or leading to haemodynamic compromise within this period. Patient characteristics were recorded through the use of case record forms. Patients in whom 24-hour Holter registration could not be obtained were excluded.

Analysis of heart rate variability
Time and frequency domain indices of heart rate variability were analysed according to the recommendations of Task Force of the European Society of Cardiology (ESC) (18). Standard deviation of R-R intervals (SDNN), SDNN index (SDNNi) is a measure of variability due to cycles shorter than 5 minutes, standard deviation of average NN intervals (SDANN), the number of interval differences of successive NN intervals greater than 50 ms (NN50)/total number of NN intervals (pNN50) and square root of the mean squared differences of successive NN intervals (RMSSD) were analysed. Patients with atrial fibrillation, or rhythm disturbances that could interfere with accurate heart rate variability analysis (e.g. frequent ectopic beats, rhythm induced by pacemaker), and patients with inadequate recordings were excluded.  

Infarct size
Infarct size was assessed using Creatine kinase (n=79) and Troponin T (n=79) Area under the curve (AUC) or Cardiac Magnetic Resonance Imaging (CMR) (n=68) as previously described (15). 

Data and statistical analysis
Analysis was performed using GraphPad™ Prism software version 5.0 for Mac OsX and SPSS version 19, (SPSS Inc, Chicago, Ill). All p values are 2 sided and the border of significance accepted as p<0.05. Analysis was based on the intention-to-treat principle. Baseline demographic and clinical variables were summarised for each arm of the study. Descriptive summaries of the distributions of continuous baseline variables are presented in terms of percentiles (e.g. median, 25th and 75th percentile), while discrete variables are summarised in terms of frequencies and percentages. Comparisons are between the sodium nitrite-treated and placebo control-treated group. Statistical analyses were conducted blind to the treatment groups. For comparisons between normally distributed data statistical comparisons were performed using unpaired t-tests and non-normally distributed data with non-parametric testing (Mann-Whitney). Determination of correlations were performed using the Pearson’s correlation coefficient analysis of least-squares and expressed as 95% confidence intervals. 




Results

80 patients were recruited into NITRITE-AMI (40 in the control group and 40 in the nitrite group). All 80 patients underwent 24 hour Holter monitoring, however one had an incomplete dataset and was excluded leaving a total of 79 patients with analysable data. As previously reported in the main NITRITE-AMI study, cohort baseline characteristics are shown in table S1, and were similar between the treatment groups. Aside from the study IMP, both groups no differences in treatment (medication), timing of medication intiation or devices were seen between the 2 groups either pre, post PCI and out to 12 months (Table 1). The mean age of the trial participants was 57 years, with 84% male. 25% of the cohort had anterior infarcts with similar numbers in both treatment groups. Stenting of the culprit lesion was performed in 97.5% of all patients. For full details see Jones et al(). 

Incidence of Arrhythmias
Overall ventricular rhythm disturbance was experienced by all 79 (100%) patients. All patients experienced isolated ventricular ectopics (median 433, IQR 137-1061), 94% of patients experienced ventricular couplets (median 12, IQR 4-35), 77% of patients experienced accelerated idioventricular rhythm (median 11 beats, IQR 3-42) and 78% of patients experienced NSVT (median 20 beats, IQR 3-60). Over the 24 hour period 46.8% of the arrhythmias seen occurred in the 1st 8 hours, with 33% between 8-16 hours and the remaining 20.2% between 16 and 24 hours. Both NSVT and AIDR were seen throughout the 24 hour period however in the first 8 hours, 63.2% of the arrhythmias seen were AIDR and in the last 8 hours 82.1% of the arrhythmias were NSVT indicating a predominance of AIDR earlier in the time period. 


No patients had episodes of either sustained VT or ventricular fibrillation (VF) post IMP delivery, although 2 patients required defibrillation for pulseless VT/VF prior to the primary PCI. These 2 patients were successfully treated with primary PCI post defibrillation (both with 1 x shock), both with drug-eluting stents to the circumflex. Both had uncomplicated in-patient courses being discharged without complication. 

Overall there was no difference in the incidence of total ventricular ectopic burden between the 2 treatment groups either as a total number of VEs (Nitrite median VEs 398 (IQR 104-1253) vs placebo 497 (297-1007), p=0.2196) or as a percentage of total ventricular activity (Nitrite 0.35% (0.09-1.25) vs placebo 0.46 (0.25-0.93), P=0.1917) (Figure 1). Additionally, no difference was seen in the incidence of couplets between the 2 treatment groups (p=0.81).  The incidence of VEs was positively correlated with myocardial infarct size as assessed by both cardiac enzymes (r=0.277, p=0.014) and CMR (r=0.316, p=0.012) (Figure S1). 
No differences were seen between the medication/treatment between the study 

NSVT was reduced by nitrite treatment 
NSVT occurred in 67.5% (27/40) of nitrite-treated patients compared to 89% (35/39) of those treated with placebo (p=0.027). In addition, both the number of runs (63%, p=<0.0001) and total beats of NSVT (64%, p=0.0019) were reduced in the nitrite-treated patients compared to those who received placebo (Figure 2). Similar reductions were seen in both the 1st (p=0.001) and 2nd (p=0.0012) 12 hours of the Holter monitoring period. Post-hoc correlation analyses demonstrate an association between the occurrence of NSVT with infarct size assessed by cardiac enzymes (Figure S2A). This correlation was stronger in the placebo versus the nitrite group suggesting an independent effect of nitrite (Nitrite: r=0.110, p=0.499, placebo:  r=0.527, p=0.001, p for comparison (correlations): 0.004) (Figure S2B).  As well as being associated with infarct size post-hoc analyses demonstrated that NSVT was inversely correlated with the myocardial salvage index (r=-0.291, p=0.023).  



Accelerated Idioventricular Rhythm (AIDR)
AIDR occurred in 90% (36/40) of nitrite-treated patients compared to 64% (25/39) of those treated with placebo (p=0.0075). In addition, there was a greater number of runs (12%, p=0.0017) and total beats (17%, p=0.0074) of AIDR in the nitrite-treated patients compared to the placebo-treated group. Post-hoc analyses demonstrate that AIDR is directly correlated with myocardial salvage index (r=0.268, p=0.035) and negatively correlated with both the presence of (p=0.027, r=-0.270) and amount of microvascular obstruction (p=0.04,r=-0.247).

Heart rate variability 
The main heart rate variability parameters post-STEMI are reported in Table 2.  We found no statistically significant differences in any of the heart rate variability parameters measured in our group of post-AMI patients between cases with or without nitrite treatment (see Table 2).

Nitrite reduces MACE at 6 month post intervention
There was a significant reduction in MACE at 6 months in the nitrite group compared to the placebo group (7.7% versus 0%, p=0.48). Post-hoc analyses demonstrated that both runs (r=0.320, p=0.004) and beats (r=0.376, p=0.001) of NSVT were positively correlated with 6 month MACE whilst the total number of runs (r=-0.253, p=0.025) and beats (r=-0.252, p=0.026) of AIDR were negatively correlated with event rates. We have previously shown that nitrite treatment was associated with reduced 3 year MACE (20), attributed to the anti-inflammatory effect of nitrite, however the reduced arrhythmia associated with nitrite treatment may be contributing to this MACE benefit especially with reduced short term events.





Discussion

This is the first study to demonstrate that the administration of intra-coronary inorganic nitrite during primary PCI significantly reduces the occurrence of NSVT in patients with AMI. Investigations have shown that 90% of VT and VF events occur within the first 48 hours after primary PCI but perhaps more importantly these arrhythmias are not benign with their occurrence associated with a considerable increase in morbidity and 90-day mortality (19). Thus, the beneficial effect of sodium nitrite in this context described in this manuscript identifies a novel approach to reduction of ventricular arrhythmias post-PCI and importantly is likely to underlie, at least in part, some of the long-term benefits evident with nitrite treatment on MACE in the NITRITE-AMI trial (20).

Previous studies in man using organic nitrates to deliver NO have demonstrated some suppression of I/R induced arrhythmias (4, 5). Although the precise mechanisms of these antiarrhythmic effects have not been fully elucidated, studies have revealed that nitroglycerin causes electrophysiological alterations in the human heart (4), and reduces ectopic activity during AMI (5). In the NITRITE-AMI cohort all patients experienced acute ventricular ectopic beats but overall over the 24h period of assessment we did not see a difference between the nitrite-treated and placebo-treated groups.  Further analysis of this data did, however, expose some interesting differences.  Our analyses show that whilst the total number and incidence did not change that separation of the arrhythmias in to different types exposed a substantial and significant attenuation of the number of NSVT. This observation is of importance since the incidence of NSVT, at least in the in-hospital period beyond 24h, does have adverse prognostic significance (19, 21, 22). 

In Nitrite-AMI the primary outcome was a surrogate measure of outcome i.e. infarct size assessed by creatine kinase (CK) with CMR determined infarct size as a powered secondary outcome. Importantly, in the whole cohort CK was not different between the treatment groups and infarct size assessed by CMR only trending to a difference. Assessment of both measures only in those with TIMI 0-1 at the time of reperfusion, however, exposed clear differences between the groups in both measures. In contrast, we have previously reported a substantially lower number of MACE events in those patients in the NITRITE-AMI cohort receiving nitrite compared to the placebo (15, 20) in the whole cohort, despite an absence of effect upon the primary outcome measure. Indeed, MACE events were 75% lower in the nitrite-treated group suggesting that effects other than a reduction in infarct size might underlie the reduced MACE. Our data herein, suggest that a reduced incidence of NSVT may have a role to play. In support of this, in correlation analyses separating out the two treatment groups indicate that the reduced NSVT in the nitrite group is not associated to the levels of cardiac enzyme and hence due to an effect independent of infarct size. 

The exact mechanism of the nitrite-induced reduction in NSVT is uncertain,.  however the mechanisms underlying the beneficial effects of nitrite are attributed to its conversion to nitric oxide, the half-life of which is very short (seconds) meaning any specific anti-arrhythmic effects are likely to occur early after administration.  There is some suggestion that S-nitrosation of key proteins involved in the respiratory chain might have a role (16), although such an effect would lead to a generalized improvement in the total number of beats which was not evidenced in this study. Interestingly, experimental evidence in dogs suggests that NO likely improves cardiac arrhythmias and specifically NSVT through S-nitrosation of the connexin protein Cx43 that plays an important role in gap-junction mediated transfer of small molecules. This activity is driven by the phosphorylation of the gap junction protein resulting in enhanced coupling between cardiac myocytes, and possibly improving the transfer of cGMP between cells (3). In addition, there have been numerous observations demonstrating that NO can interfere with channel activity underlying the cardiac myocyte action potential. Indeed, every single channel involved in each step of the action potential is sensitive to modulation by NO (23).  In particular evidence suggests that for NSVT prolongation of hyperpolarization, through the opening of K channels (specifically delayed rectifier currents) and/or shortening of the depolarisation period through modulation of the opening of the L-type calcium channel, play a key role in the presence of NSVT (23). It is possible therefore that these channels are the target for NO activity. 

In the literature, the commonest recorded reperfusion arrhythmia after primary PCI is AIDR, which has been shown to occur in 40-81% of cases (24, 25); and the outcomes reported for the NITRITE-AMI cohort herein are in agreement with this, with this being (at 77%) the commonest arrhythmia seen aside from isolated VEs. AIDR may indicate successful reperfusion (26), but also may be associated with a greater degree of myocardial damage (27), with mixed reports published to date. In this study AIDR was associated with reduced MVO (marker of I/R injury) and a greater MSI supporting the view that AIDR is a marker of successful reperfusion and potentially more specifically an indicator of microvascular perfusion. AIDR is thought to be due to abnormal automaticity, the accelerated generation of an action potential by a region of ventricular cells, and is related to the acute phase of the AMI (28). Studies on the association between NO and automaticity, specifically the ventricular action potential, suggest that NO may mediate prolongation of action potential duration or ventricular repolarization in a number of pathophysiological conditions including I/R injury (29). Models have demonstrated that an increase in endogenous NO levels is associated with a prolongation of the action potential duration of ventricular myocytes (30) whereas inhibition of NO synthesis accentuates ischaemia-induced reduction in action potential duration (31).  In addition, the administration of NO donors (sodium nitroprusside) decreases the duration of repolarization and increases the pacemaker activity of the isolated guinea pig sinus node (32). An effect on automaticity in this group could be suggested by the marginally higher HRV values seen in the nitrite treated group however these did not reach statistical significance. Although the exact mechanisms underlying the higher rates of this rhythm disturbance within the nitrite treated group are unclear, our data does suggest a greater degree of successful reperfusion and reduced I/R injury with nitrite therapy.  

The role of nitrite in the protection of the heart from injury has been studied extensively in animal models, and it is becoming increasingly obvious that nitrite provides significant protection against cell death and cardiac dysfunction with extensive pre-clinical evidence demonstrating the cytoprotective properties of nitrite in models of myocardial infarction (12, 13, 33, 34) and in other organs, including the liver (13), kidney (34) and brain (35). The effects of nitrite or NO on ventricular arrhythmias following AMI however are less well studied. Coronary endothelial dysfunction and NOS inhibitors reduce coronary effluent NO levels and increase the incidence and severity of ventricular arrhythmias in rat models of I/R (36). In contrast, L-arginine (37) and NO donors, even at subvasodilatory doses, reduce I/R-induced ventricular fibrillation (VF) in rats and dogs (38, 39). One recent study (16) has assessed the role of inorganic nitrite in anaesthetised dogs demonstrating that the intravenous infusion of the anion markedly reduces the severity of ventricular arrhythmias resulted from a 25 min occlusion and reperfusion of the LAD. This antiarrhythmic effect was particularly pronounced when the infusion of nitrite was started 10 min prior to reperfusion.  To date no animal models have assessed the effect of topical or intracoronary nitrite on reperfusion arrthymias. 

In this group of STEMI patients treated with primary PCI, abnormal autonomic parameters (evidenced by low HRV) were only found in a small percentage of patients with no difference in HRV seen between treatment groups. This finding is in keeping with the recent literature, which has suggested that HRV seems to have lost its prognostic significance in the era of primary PCI, (40) while parameters indicating LV function (such as LVEF and - partly - physical performance) could allow better prognostication in primary-PCI STEMI patients. 



Limitations

NITRITE-AMI was powered off a reduction in myocardial infarct size rather than the incidence of ventricular rhythm disturbance meaning the study may lack power. The data in this manuscript, however, are hypothesis generating with a strong signal suggestive of a nitrite effect. Further prospective studies powered to measure differences in ventricular rhythm disturbance to confirm these observations are now warranted.

Conclusion

Overall no difference in ventricular rhythm disturbance was seen with intra-coronary nitrite treatment during primary PCI in STEMI patients, however nitrite treatment was associated with an important reduction in the incidence and severity of NSVT but an increase in AIDR. In view of the sustained reduction of MACE, this effect warrants further study in a large-scale trial.  
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Tables
	Nitrite		Placebo	P value
Medication pre PCI				
  Morphine	17 (43.3%)		22 (55.0%)	0.371
  Heparin	40 (100%)		39 (100%)	1.000
  Aspirin	40 (100%)		39 (100%)	1.000
  Clopiodgrel/Prasugrel	35/5		36/3	0.712
  GPIIb/IIIa inhibitor	40 (100%)		39 (100%)	1.000
  GTN Use	18 (45.0%)		18 (46.1%)	1.000
Procedural Devices	(n=40)		(n=39)	
  DES use	33 (82.5%)		30 (78.9%)	0.778
  Thrombectomy use	31 (82.5%)		31 (77.5%)	0.781
Medication post PCI 	(n=40)		(n=39)	
  ACE inhibitor	39 (97.5%)		36 (92.3%)	0.359
  ARB	1 (2.5%)		2 (5.1%)	0.556
  Ivabradine	1 (2.5%)		0 (0%)	0.314
  Beta-Blocker	37 (92.5%)		36 (92.3%	0.692
   Atorvastatin	40 (100%)		39 (100%)	1.000
   Aspirin	40 (100%)		39 (100%)	1.000
   Clopidogrel	37(92.5%)		36 (92.3%)	0.956
   Prasugrel	3 (7.5%)		3 (7.7%)	0.644
Medication at 1 year	(n=39)		 (n=39)	
   ACE inhibitor	36 (92.3%)		34 (87.2%)	0.455
   ARB	3 (7.7%)		4 (10.3%)	0.692
   Diuretic	2 (5.1%)		2 (5.1%)	1.000
   Spironolactone	0 (0.0%)		1 (100)	0.314
   Ivabradine	2 (5.1%)		0 (0.0%)	0.147
   β Blocker	36 (92.3%)		34 (87.2%)	0.455
   Statin	39 (100%)		39 (100%)	1.000
   Aspirin	39 (100%)		39 (100%)	1.000
   Clopidogrel	35 (89.7%)		35 (89.7%)	1.000
   Prasugrel	3 (7.7%)		3 (7.7%)	0.644
   Organic Nitrate	0 (0.0%)		1 (2.6%)	0.314

Table 1.   Medication pre- and post-procedure by treatment group


Table 2.   Ventricular rhythm and cardiac magnetic resonance data
	Placebo	Nitrite		
	(n=39)	(n=40)		p value
VE (median beats)	497 (297-1007)	398 (104-1253)		0.2196
VEs (%)	0.46 (0.25-0.93)	0.35 (0.09-1.25)		0.1917
Couplets (median)	13 (6.3-32)	12 (3.3-43)		0.8067
				
HRV Parameters				
SDNN, ms	94.0±29.9	100.4±24.4		0.1050
RMSSD, ms	25.1±9.9	31.1±19.7		0.1703
SDANN, ms	75.2±26.6	82.2±19.3		0.2902
SDNN-I, ms	50.9±17.7	52.4±23.6		0.8063
				
Infarct size				
Creatine Kinase AUC	48,195 (27,796-82841)	56398 (31185-83531)		0.920
Troponin T AUC	136,412 (70045-239483)	140782 (84949-218133)		0.850
				
CMR Parameters	(n=33)	(n=35)		
LVEDVi	76.13 (71.11-81.14)	70.58 (65.22-75.94)		0.13
LVESVi	36.16 (32.56-39.75)	35.71 (30.94-40.48)		0.88
LVEF	52.87 (49.88-55.86)	50.07 (46.46-53.67)		0.23
Infarct size (% LV)	17.10 (14.12-20.08)	19.55 (16.40-22.70)		0.25
Area At Risk	34.58 (31.62-37.55)	33.05 (29.40-36.72)		0.52
MSI	0.52 (0.46-0.58)	0.44 (0.39-0.49)		0.05
MVO				
  No. (%)	16 (48.5%)	23 (69.7%)		0.13
  Amount (median (IQR)	2.98 (0-6.25)	3.47 (0-4.75)		0.34

Values shown as mean (95% CI). Abbreviations: LVEDVi, Indexed left ventricle end-diastolic volume; LVESVi, Indexed left ventricle end-systolic volume; LVEF, left ventricle ejection fraction; MSI, myocardial salvage index; MVO, microvascular obstruction; SDNN, Standard deviation of R-R intervals; SDNNi, variability due to cycles shorter than 5 minutes; SDANN, standard deviation of average NN intervals; RMSSD, square root of the mean squared differences of successive NN intervals



Figure 1. Total Ventricular ectopic burden is unchanged by intra-coronary sodium nitrite treatment in STEMI patients undergoing primary PCI. Panel A shows a similar incidence of total ventricular ectopic beat numbers between the two treatment groups whilst panel B displays the VE percentage of total ventricular activity. Significance evaluated using Mann-Whitney test and data shown as mean ± SEM of n=79. 



Figure 2. Non-sustained VT and nitrite treatment. Panel A displays the total number of NSVT beats comparing nitrite and placebo groups with panel B displaying the number of runs of NSVT.  The mean number of runs and total beats were significantly fewer in the nitrite group compared to the control group. Significance evaluated using Mann-whitney test and data shown as mean ± SEM (n=79) 
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